[PDF][PDF] Peptide antigen treatment of naive and virus-immune mice: antigen-specific tolerance versus immunopathology

P Aichele, K Brduscha-Riem, S Oehen, B Odermatt… - Immunity, 1997 - cell.com
P Aichele, K Brduscha-Riem, S Oehen, B Odermatt, RM Zinkernagel, H Hengartner…
Immunity, 1997cell.com
Peptide-specific down-regulation of T cell responses may represent a powerful tool to
intervene in autoimmune diseases or graft rejections. It is therefore important to know
whether peptide treatment tolerizes both naive and antigen-experienced memory T
lymphocytes. Here we show that a major histocompatibility complex class I binding peptide,
derived from the glycoprotein (GP33 peptide) of lymphocytic choriomeningitis virus (LCMV),
specifically tolerized naive cytotoxic T lymphocytes (CTL) when administered three times …
Abstract
Peptide-specific down-regulation of T cell responses may represent a powerful tool to intervene in autoimmune diseases or graft rejections. It is therefore important to know whether peptide treatment tolerizes both naive and antigen-experienced memory T lymphocytes. Here we show that a major histocompatibility complex class I binding peptide, derived from the glycoprotein (GP33 peptide) of lymphocytic choriomeningitis virus (LCMV), specifically tolerized naive cytotoxic T lymphocytes (CTL) when administered three times intraperitoneally in incomplete Freund's adjuvants. However, in the presence of GP33-specific memory CTL in LCMV-primed mice, the same treatment had a general immunosuppressive effect on unrelated third-party antigen-specific T cell responses and caused severe immunopathological damage to the spleen.
cell.com